Dos and don’ts in pain management in multiple myeloma
During the Multiple Myeloma Hub Symposium on Nov 10, 2022, Flaminia Coluzzi provided a presentation on the dos and don’t in pain management, which can now be viewed on-demand.
Related Articles
Symposium | Practical management of adverse events with immunotherapies
During the Multiple Myeloma Hub virtual symposium held on March 11, 2024, “Current and future perspectives for bispecific antibodies in multiple myeloma: Lea…
Symposium | Introduction to T-cell engagers and general mechanism of action
On March 11, 2024, the Multiple Myeloma Hub hosted a virtual symposium, “Current and future perspectives for bispecific antibodies in multiple myeloma: Learn…
OPTIMISMM trial: A subanalysis by frailty and bortezomib dose adjustment
Here, we summarize a subanalysis by Oriol et al. published in Clinical Lymphoma, Myeloma and Leukemia on the results of the OPTIMISMM trial by frailty…
Symposium | Introduction to T-cell engagers and general mechanism of action
The Multiple Myeloma Hub virtual symposium was chaired by Sagar Lonial, and featured expert presentations from Naresh Bumma, Amrita Krishnan, and Sergio Giralt.
Infections following bispecific antibody therapy in MM: incidence and characteristics
Here, we summarize a multicenter, retrospective study conducted in France on the incidence and characteristics of infections following treatment with bispecific antibody therapy.
Approaches to measuring frailty in MM: Comparison of IMWG FI and PRFP
Here, we summarize a publication by Murugappan, et al. in Journal of Geriatric Oncology on a comparison between approaches to measuring frailty: the patient-reported frailty…
Symposium | Introduction to T-cell engagers and general mechanism of action
The Multiple Myeloma Hub virtual symposium was chaired by Sagar Lonial, and featured expert presentations from Naresh Bumma, Amrita Krishnan, and Sergio Giralt.
FDA approves idecabtagene vicleucel for triple-class-exposed RRMM
On April 5, 2024, the U.S. FDA granted approval to idecabtagene vicleucel for the treatment of triple-class-exposed relapsed/refractory multiple myeloma after two or more prior…
CAR T-cell therapy in older patients: Efficacy and rates of immune-mediated toxicity
We summarize a systematic review and meta-analysis by Akhtar et al. investigating the efficacy of CAR T-cell therapy and rates of immune-mediated toxicity in patients…
Integrating cilta-cel into earlier lines of therapy: Rationale and latest data from CARTITUDE-2 and CARTITUDE-4
Here we summarize the rationale and latest clinical trial data investigating the use of cilta-cel in earlier lines of therapy in multiple myeloma.